The Supreme Court granted Covidien Limited leave to appeal on 24 July 2025. The case is a VAT dispute with the Revenue Commissioners. The panel was Dunne J, Woulfe J and Hogan J.
Revenue raised VAT assessments between August 2015 and March 2017. It claimed Covidien was liable for sums approximating to some €46m. Covidien appealed to the Tax Appeal Commissioners, who upheld its appeal. The High Court, under Nolan J., affirmed that decision.
The Court of Appeal then allowed Revenue's appeal. Hyland J. found the commissioner had not properly applied the "used for" test. That test is in Article 168 of the VAT Directive. The court directed a rehearing before the commissioners. Covidien applied for leave on 29 May 2025.
The dispute is about input VAT. Covidien says it can deduct all of it. Revenue says only part is deductible. Revenue has allowed 40% on the tax charged on services from Tyco Healthcare Group. Covidien is the holding company of the Covidien Group, which makes healthcare products.
Covidien said the Court of Appeal reached its view without findings of fact in the case stated. It also raised wider questions on VAT deductibility, including the role of dormant group companies. Revenue opposed leave. It said the case applied established VAT principles.
The Supreme Court found the application raised matters of general public importance. It said the deductibility rules matter beyond multinationals, to businesses with holding companies generally. It said clarification was desirable. The court accepted the appeal might turn on established principles. But it could not say no important questions of law arise on the "used for" test.